Increased Plasma Heparanase Activity in COVID-19 Patients.
Aged
Betacoronavirus
COVID-19
Coronavirus Infections
/ immunology
Creatinine
/ blood
Critical Care
Cross-Sectional Studies
Endothelium
/ pathology
Female
Glucuronidase
/ antagonists & inhibitors
Heparin Antagonists
/ therapeutic use
Heparin, Low-Molecular-Weight
/ therapeutic use
Heparitin Sulfate
/ blood
Humans
Interleukin-6
/ blood
L-Lactate Dehydrogenase
/ blood
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ immunology
SARS-CoV-2
Tight Junctions
/ pathology
COVID-19
LMWH (low molecular weight heparin)
glycocalyx damage
heparanase
inflammation
vascular leakage
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
06
2020
accepted:
14
09
2020
entrez:
30
10
2020
pubmed:
31
10
2020
medline:
11
11
2020
Statut:
epublish
Résumé
Reports suggest a role of endothelial dysfunction and loss of endothelial barrier function in COVID-19. It is well established that the endothelial glycocalyx-degrading enzyme heparanase contributes to vascular leakage and inflammation. Low molecular weight heparins (LMWH) serve as an inhibitor of heparanase. We hypothesize that heparanase contributes to the pathogenesis of COVID-19, and that heparanase may be inhibited by LMWH. To test this hypothesis, heparanase activity and heparan sulfate levels were measured in plasma of healthy controls (n = 10) and COVID-19 patients (n = 48). Plasma heparanase activity and heparan sulfate levels were significantly elevated in COVID-19 patients. Heparanase activity was associated with disease severity including the need for intensive care, lactate dehydrogenase levels, and creatinine levels. Use of prophylactic LMWH in non-ICU patients was associated with a reduced heparanase activity. Since there is no other clinically applied heparanase inhibitor currently available, therapeutic treatment of COVID-19 patients with low molecular weight heparins should be explored.
Identifiants
pubmed: 33123154
doi: 10.3389/fimmu.2020.575047
pmc: PMC7573491
doi:
Substances chimiques
Heparin Antagonists
0
Heparin, Low-Molecular-Weight
0
IL6 protein, human
0
Interleukin-6
0
Heparitin Sulfate
9050-30-0
Creatinine
AYI8EX34EU
L-Lactate Dehydrogenase
EC 1.1.1.27
heparanase
EC 3.2.1.-
Glucuronidase
EC 3.2.1.31
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
575047Informations de copyright
Copyright © 2020 Buijsers, Yanginlar, de Nooijer, Grondman, Maciej-Hulme, Jonkman, Janssen, Rother, de Graaf, Pickkers, Kox, Joosten, Nijenhuis, Netea, Hilbrands, van de Veerdonk, Duivenvoorden, de Mast and van der Vlag.
Références
Arterioscler Thromb Vasc Biol. 2013 Feb;33(2):e56-65
pubmed: 23162016
Nat Med. 2012 Aug;18(8):1217-23
pubmed: 22820644
Am J Physiol Heart Circ Physiol. 2008 Feb;294(2):H651-8
pubmed: 18032524
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Matrix Biol. 2013 Jun 24;32(5):234-240
pubmed: 23499528
Am J Pathol. 2016 Apr;186(4):805-15
pubmed: 26873445
J Clin Med. 2020 May 11;9(5):
pubmed: 32403217
J Cell Sci. 2004 May 1;117(Pt 11):2249-58
pubmed: 15126626
EBioMedicine. 2020 Sep;59:102969
pubmed: 32853989
Curr Drug Discov Technol. 2009 Dec;6(4):281-9
pubmed: 20025596
J Am Soc Nephrol. 2016 Dec;27(12):3545-3551
pubmed: 27026367
Cardiovasc Res. 2004 Jan 1;61(1):159-68
pubmed: 14732213
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
Nephrol Dial Transplant. 2009 Sep;24(9):2637-45
pubmed: 19429930
Front Biosci (Landmark Ed). 2015 Jun 01;20(8):1259-70
pubmed: 25961556
Biochem Biophys Res Commun. 2014 Aug 22;451(2):263-9
pubmed: 25088996
Acad Emerg Med. 2020 Jun;27(6):493-504
pubmed: 32359203
J Thromb Haemost. 2020 May;18(5):1020-1022
pubmed: 32239799
Blood. 1987 Aug;70(2):551-7
pubmed: 2955820
Clin Med (Lond). 2020 Mar;20(2):124-127
pubmed: 32139372
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
Am J Pathol. 2017 Nov;187(11):2430-2440
pubmed: 28837800
Physiol Rev. 2008 Apr;88(2):451-87
pubmed: 18391170
J Thromb Haemost. 2020 May;18(5):1023-1026
pubmed: 32338827
Front Immunol. 2020 Oct 06;11:575047
pubmed: 33123154
Front Physiol. 2020 Oct 19;11:573044
pubmed: 33192569
Am J Respir Cell Mol Biol. 2016 Jul;55(1):5-11
pubmed: 26982577
Eur J Clin Pharmacol. 2000 Jul;56(4):293-7
pubmed: 10954342
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Rev Nephrol. 2017 Apr;13(4):201-212
pubmed: 28163306
Nephrol Dial Transplant. 2014 Jan;29(1):49-55
pubmed: 24166469
PLoS One. 2014 Oct 08;9(10):e109596
pubmed: 25295599
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
Curr Top Membr. 2018;82:33-52
pubmed: 30360782
J Am Heart Assoc. 2020 Apr 7;9(7):e016219
pubmed: 32233755
Sci China Life Sci. 2020 Mar;63(3):364-374
pubmed: 32048163
Kidney Int. 2020 Jul;98(1):209-218
pubmed: 32416116
Diabetes. 2012 Jan;61(1):208-16
pubmed: 22106160
Diabetes. 2014 Dec;63(12):4302-13
pubmed: 25008182
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
Clin Transl Sci. 2020 Nov;13(6):1087-1095
pubmed: 32881340
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Cytokine Growth Factor Rev. 2020 Jun;53:25-32
pubmed: 32446778
Cell Metab. 2014 Nov 4;20(5):813-826
pubmed: 25440058
Sci Rep. 2019 Sep 19;9(1):13591
pubmed: 31537875
Am J Physiol Lung Cell Mol Physiol. 2018 Jan 01;314(1):L17-L31
pubmed: 28935640
PLoS One. 2016 Dec 1;11(12):e0167576
pubmed: 27907146
Oncotarget. 2017 Mar 21;8(12):19403-19412
pubmed: 28038446
J Am Soc Nephrol. 2006 Sep;17(9):2513-20
pubmed: 16899518
J Immunol. 2005 Sep 1;175(5):3377-85
pubmed: 16116231
Kidney Int. 2008 Jan;73(1):52-62
pubmed: 17914352
J Pathol. 2012 Mar;226(4):562-74
pubmed: 22102407